Imatinib-based therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report and literature review

Zhang,Li; Chen,Meng; Feng,Bo; Kuang,Pu; He,Peng; Liu,Ting; Pan,Ling

doi:10.3892/ol.2015.3539

Imatinib-based therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report and literature review

Authors:
- Li Zhang
- Meng Chen
- Bo Feng
- Pu Kuang
- Peng He
- Ting Liu
- Ling Pan
View Affiliations

Affiliations: Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Third Division of Internal Medicine, District People's Hospital, Qionglai Medical Center Hospital, Qionglai, Sichuan 611530, P.R. China
Published online on: July 28, 2015 https://doi.org/10.3892/ol.2015.3539
Pages: 2051-2054
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute lymphoblastic leukemia (ALL) has a rapid onset and rarely occurs with exclusive prodrome of general osteoporosis and vertebral compression fractures. However, Philadelphia chromosome‑positive (Ph+) ALL has a poor prognosis, even when patients are treated with intensive chemotherapy, and the first‑line effective treatment requires further elucidation. The present study focused on a 56‑year‑old Chinese male patient who initially presented with spontaneous bone fractures and was ultimately diagnosed as Ph+ ALL after 6 months, which required to preliminarily exclude a working diagnosis of myeloma. Apart from intensive chemotherapy, the patient successfully completed an imatinib‑based regimen and achieved complete remission (CR) 2 weeks later. Subsequently, the patient was subjected to consolidation treatment using the same imatinib regimen combined with interferon‑α 2b for 9 courses. In November 2013, the patient had achieved persistent hematological and molecular genetic normality for ~16 months after the initial CR. In conclusion, Ph+ ALL must be considered in the differential diagnosis of adults experiencing unexplained bone disease.

View Figures

View References

1	Hunger SP and Mullighan CG: Redefining ALL classification: Toward detecting high-risk ALL and implementing precision medicine. Blood. 125:3977–3987. 2015. View Article : Google Scholar : PubMed/NCBI
2	TeWinkel ML, Peiters R, Wind EJ, Bessems JH and van den Heuvel-Eibrink MM: Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia. Haematologica. 99:430–436. 2014. View Article : Google Scholar : PubMed/NCBI
3	Nair M, Kusumakumary P and Nair PS: Rare presentation of pediatric acute promyelocytic leukemia as multiple lytic bone lesions: Case report and review of the literature. J Cancer Res Ther. 10:381–383. 2014. View Article : Google Scholar : PubMed/NCBI
4	Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, et al: Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL): Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 125:3711–3719. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ross DM, Branford S, Moore S and Hughes TP: Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia. 20:664–670. 2006. View Article : Google Scholar : PubMed/NCBI
6	Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S, Bene MC, et al: Mixed-phenotype acute leukemia: Clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 117:3163–3171. 2011. View Article : Google Scholar : PubMed/NCBI
7	Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D and Kantarjian HM: Adult acute lymphoblastic leukemia: Concepts and strategies. Cancer. 116:1165–1176. 2010. View Article : Google Scholar : PubMed/NCBI
8	Leblicq C, Laverdière C, Decarie JC, Delisle JF, Isler MH, Moghrabi A, Chabot G and Alos N: Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 60:741–747. 2013. View Article : Google Scholar : PubMed/NCBI
9	Atas A, Cakmak A, Soran M, Soker M and Varma M: Severe osteoporosis and high level TSH in a child before the diagnosis of acute lymphoblastic leukemia. J Pediat Hematol Oncol. 31:588–591. 2009. View Article : Google Scholar
10	Bertuna G, Famà P, Lo Nigro L, Russo-Mancuso G and Di Cataldo A: Marked osteoporosis and spontaneous vertebral fractures in children: Don't forget, it could be leukemia. Med Pediatr Oncol. 41:450–451. 2003. View Article : Google Scholar : PubMed/NCBI
11	Hafiz MG and Islam A: Extensive skeletal lesions in childhood acute lymphoblastic leukemia. Mymensingh Med J. 18:88–94. 2009.PubMed/NCBI
12	Hafiz MG, Islam A and Siddique R: Back pain and vertebral compression: An unusual presentation of childhood acute lymphoblastic leukemia. Mymensingh Med J. 19:130–136. 2010.PubMed/NCBI
13	Kim DH and Vaccaro AR: Osteoporotic compression fractures of the spine; current options and considerations for treatment. Spine J. 6:479–487. 2006. View Article : Google Scholar : PubMed/NCBI
14	Kaloostian PE, Zadnik PL, Etame AB, Vrionis FD, Gokaslan ZL and Sciubba DM: Surgical management of primary and metastatic spinal tumors. Cancer Control. 21:133–139. 2014.PubMed/NCBI
15	Shah NR, Landi DB, Kreissman SG, Kulbachi E and Moran C: Presentation and outcomes for children with bone marrow necrosis and acute lymphoblastic leukemia: A literature review. J Pediatr Hematol Oncol. 33:e316–e319. 2011. View Article : Google Scholar : PubMed/NCBI
16	Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, et al: Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: A 36-month analysis of a phase I and II study. Int J Hematol. 95:409–419. 2012. View Article : Google Scholar : PubMed/NCBI
17	Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, et al: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 103:4396–4407. 2004. View Article : Google Scholar : PubMed/NCBI
18	Mizuta S, Matsuo K, Maeda T, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, et al: Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. Blood Cancer J. 2:e722012. View Article : Google Scholar : PubMed/NCBI
19	Ohno R: Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig R. 5:213–221. 2010. View Article : Google Scholar
20	Philippe R, Marie M, Françoise H, et al: Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study. Blood (ASH Annual Meeting Abstracts). 120:6122012.
21	Mizuta S, Matsuo K, Yagasaki F, et al: Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia. 25:41–47. 2011. View Article : Google Scholar : PubMed/NCBI
22	Heike P, Sylvia W, Binckebanck A, et al: Imatinib (IM) and interferon-alpha (IFN-α) maintenance therapy is associated with long-term DFS in a subset of elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph ALL). Blood (ASH Annual Meeting Abstracts). 120:15032012.